Our Technology
Leadership Team
Investor Relations
About Us
Contact Us
Investor relations
News
$500m Cancer team reassembled
Published courtesy of Pharma In Focus
Tags:
News
Continue reading
ImmVirX receives $2.81M R&D tax refund for FY22
Company Announcements
May 19, 2021
by
ImmVirX receives $2.81M R&D tax refund for FY22
Company Announcements
May 19, 2021
by
AFR Higher Education Award Research Commercialisation
News
Nov 13, 2020
by
AFR Higher Education Award Research Commercialisation
News
Nov 13, 2020
by
ImmVirX reports on operations for FY22
Company Announcements
May 19, 2021
by
ImmVirX reports on operations for FY22
Company Announcements
May 19, 2021
by
Join Our Mailing List
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Our mission is to improve outcomes for patients with cancers in which immunotherapy treatments have limited effect
About Us
Our Technology
